Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity (Deficiency)

v3.21.1
Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2018 $ 36 $ 2,717,538 $ (4,270,544) $ (1,552,970)
Balance at the beginning (in shares) at Dec. 31, 2018 3,599,300      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of investor and placement agent warrants in connection with issuance of convertible notes payable, net of issuance costs [1]   617,911   617,911
Stock-based compensation: Options   21,275   21,275
Stock-based compensation: Common stock $ 2,221 6,000   6,000
Net loss     (4,132,873) (4,132,873)
Balance at the end at Dec. 31, 2019 $ 36 3,362,724 (8,403,417) (5,040,657)
Balance at the end (in shares) at Dec. 31, 2019 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock and warrants in initial public offering, net of issuance costs [2] $ 25 10,605,720   10,605,745
Issuance of common stock and warrants in initial public offering, net of issuance costs (in shares) [2] 2,500,000      
Conversion of notes payable and accrued interest into common stock and warrants $ 15 7,304,815   7,304,830
Conversion of notes payable and accrued interest into common stock and warrants (in shares) 1,461,090      
Conversion of notes payable and accrued interest into common stock $ 1 388,143   388,144
Conversion of notes payable and accrued interest into common stock (in shares) 94,223      
Issuance of common stock and warrants in follow-on public offering, net of issuance costs (in shares) 4,058,822      
Issuance of common stock and warrants in follow-on public offering, net of issuance costs $ 41 18,889,872   18,889,913
Stock-based compensation: Options   19,570   19,570
Stock-based compensation: Common stock $ 38,433 154,922   154,922
Forgiveness of accrued expenses by related party   33,738   33,738
Effect of reverse stock split (in shares) 20      
Exercise of warrant (In shares) 2,000      
Exercise of warrant   11,000   11,000
Net loss     (7,885,660) (7,885,660)
Balance at the end at Dec. 31, 2020 $ 118 $ 40,770,504 $ (16,289,077) $ 24,481,545
Balance at the end (in shares) at Dec. 31, 2020 11,756,109      
[1] Net of issuance costs of $127,122.
[2] Includes gross proceeds of $12,503,750, less issuance costs of $1,898,005.